97 related articles for article (PubMed ID: 9183666)
21. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
22. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
23. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
[TBL] [Abstract][Full Text] [Related]
24. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Cortez D; Kadlec L; Pendergast AM
Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of Bcr-Abl-induced oncogenesis.
Gishizky ML
Cytokines Mol Ther; 1996 Dec; 2(4):251-61. PubMed ID: 9384712
[TBL] [Abstract][Full Text] [Related]
26. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
Wilson-Rawls J; Xie S; Liu J; Laneuville P; Arlinghaus RB
Cancer Res; 1996 Aug; 56(15):3426-30. PubMed ID: 8758906
[TBL] [Abstract][Full Text] [Related]
27. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
28. PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
Jain SK; Susa M; Keeler ML; Carlesso N; Druker B; Varticovski L
Blood; 1996 Sep; 88(5):1542-50. PubMed ID: 8781408
[TBL] [Abstract][Full Text] [Related]
29. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway.
Tauchi T; Yoshimura A; Ohyashiki K
Exp Hematol; 2001 Mar; 29(3):356-61. PubMed ID: 11274764
[TBL] [Abstract][Full Text] [Related]
30. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Ilaria RL; Van Etten RA
Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
[TBL] [Abstract][Full Text] [Related]
31. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
LaMontagne KR; Flint AJ; Franza BR; Pandergast AM; Tonks NK
Mol Cell Biol; 1998 May; 18(5):2965-75. PubMed ID: 9566916
[TBL] [Abstract][Full Text] [Related]
32. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
Puil L; Liu J; Gish G; Mbamalu G; Bowtell D; Pelicci PG; Arlinghaus R; Pawson T
EMBO J; 1994 Feb; 13(4):764-73. PubMed ID: 8112292
[TBL] [Abstract][Full Text] [Related]
33. SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase.
Tauchi T; Feng GS; Shen R; Song HY; Donner D; Pawson T; Broxmeyer HE
J Biol Chem; 1994 May; 269(21):15381-7. PubMed ID: 8195176
[TBL] [Abstract][Full Text] [Related]
34. Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase.
Gotoh A; Miyazawa K; Ohyashiki K; Toyama K
Leukemia; 1994 Jan; 8(1):115-20. PubMed ID: 8289476
[TBL] [Abstract][Full Text] [Related]
35. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.
Goga A; McLaughlin J; Afar DE; Saffran DC; Witte ON
Cell; 1995 Sep; 82(6):981-8. PubMed ID: 7553858
[TBL] [Abstract][Full Text] [Related]
36. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.
Meyn MA; Wilson MB; Abdi FA; Fahey N; Schiavone AP; Wu J; Hochrein JM; Engen JR; Smithgall TE
J Biol Chem; 2006 Oct; 281(41):30907-16. PubMed ID: 16912036
[TBL] [Abstract][Full Text] [Related]
37. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
Pendergast AM; Muller AJ; Havlik MH; Maru Y; Witte ON
Cell; 1991 Jul; 66(1):161-71. PubMed ID: 1712671
[TBL] [Abstract][Full Text] [Related]
38. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.
Pendergast AM; Gishizky ML; Havlik MH; Witte ON
Mol Cell Biol; 1993 Mar; 13(3):1728-36. PubMed ID: 8441409
[TBL] [Abstract][Full Text] [Related]
39. Autoinhibition of Bcr-Abl through its SH3 domain.
Smith KM; Yacobi R; Van Etten RA
Mol Cell; 2003 Jul; 12(1):27-37. PubMed ID: 12887890
[TBL] [Abstract][Full Text] [Related]
40. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
McWhirter JR; Galasso DL; Wang JY
Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
